Variant translocation with a deletion of derivative (9q) in a case of Philadelphia chromosome positive (Ph +) essential thrombocythemia (ET), a variant of Chronic Myelogenous Leukemia (CML) with a poor prognosis

K. DALY1, S. V. NANDULA2, V. V. MURTY2, & G. NICHOLS1

1Department of Medicine and 2Department of Pathology, Columbia University College of Physicians and Surgeons, New York, USA

Abstract
Patients presenting with thrombocytosis require thorough clinical and laboratory evaluation to determine whether they suffer from essential thrombocythemia or another myeloproliferative disorder. This distinction becomes increasingly relevant as targeted agents become available to treat specific myeloproliferative diseases. Cytogenetic testing plays a major role in this analysis. This study presents a patient with Philadelphia chromosome positive (Ph +) thrombocytosis and a cryptic der(9q)t(5;9)t(9;22) not found by conventional cytogenetics, whose disease progressed within 2 years to typical myeloblastic crisis of CML. It discusses the entity of Ph + ET, the utility of molecular cytogenetic testing in the diagnosis of this unusual disease entity and the importance of cytogenetic testing in the prognosis of ET.

Keywords: Variant Philadelphia chromosome, essential thrombocythemia, der(9q), chronic myelogenous leukemia

Introduction
Essential thrombocythemia (ET) is a myeloproliferative disorder presenting with elevated platelets, similar to chronic myelogenous leukemia (CML). The significant overlap in clinical presentation between CML and ET has led to the wide acceptance that cytogenetic and molecular analyses are appropriate in all patients with unexplained thrombocytosis, although controversies still remain regarding the appropriate classification of BCR-ABL fusion positive cases presenting as ET [1]. Whether these patients are ultimately classified as CML or ET with a BCR-ABL fusion is less important than the separation of the ‘BCR/ABL-positive ET’ group of patients from those with ‘BCR/ABL-negative ET’, as the natural history of these two disease entities is distinct [1–3]. A recent review of Ph + ET noted that 10 of 16 cases terminated in a disease similar to CML blast crisis [2] and median survival was noted to be 5 – 7 years [1,3], intermediate between CML and ET [4]. As has clearly been described in previous case reports and case series, more than half of BCR/ABL-positive ET patients will progress to the blast phase of CML [1,2] which has important implications for treatment and follow-up of this group of patients. In patients in whom only PCR positivity for BCR/ABL is found, the disease may not differ from PCR negative ET [5–7]. However, the diagnosis of Ph + ET with cytogenetic positive BCR-ABL can be regarded as an early manifestation of the chronic stable phase of CML and usually represents a variant of chronic phase CML [2,3,8]. Cases described as Ph + ET have normal WBC counts, often a normal LAP score, rare splenomegaly and may have thrombotic complications similar to Ph-negative ET, unlike most patients with chronic phase CML and thrombocytosis. The megakaryocytes in Ph + ET and Ph + thrombocythemia associated with CML are smaller than normal and typically have hypolobulated nuclei and this contrasts with the findings of clustered mature and enlarged megakaryocytes in Ph-negative ET [8]. These clinical differences highlight the importance of cytogenetic testing in patients who present with ET, even though Ph + ET is rare, as prognosis may be significantly altered by this additional diagnosis. Specific therapies directed against the ABL kinase may be appropriate for patients with Ph + ET with potential relevance for overall prognosis and survival.
A verified stepwise diagnostic testing algorithm for the exclusion of the BCR/ABL gene fusion products in ET has yet to be devised. Similar to CML, multiple diagnostic modalities may be employed to exclude the BCR/ABL gene fusion product, including traditional karyotype analysis, reverse transcription-polymerase chain reaction (RT-PCR) and single fusion or double fusion probe fluorescence in situ hybridisation (FISH). Recently, FISH capable of identifying deletions in the derivative chromosome 9 has received attention because such deletions are a powerful and independent marker for poor prognosis in CML [9–12], even with the addition of imatinib to the treatment regimen [13]. This study reports a case of Ph + ET in a patient with a poor prognosis der(9) deletion whose disease terminated in a myeloblastic crisis. The case illustrates the importance of evaluating patients with thrombocytosis for BCR/ABL and reinforces the concept that Ph + ET has the potential to evolve clinically in a fashion more similar to CML than Ph—ET.

Case history
A 73-year-old man from the Dominican Republic, with a past medical history significant for hypertension and no known family history of malignancy, presented to his physician in the Dominican Republic in September 2001 when he noticed his toenails and fingernails appeared black. The patient was found to be thrombocytopenic with a normal WBC and differential. He was diagnosed with small vessel thromboses. A sternal bone marrow aspiration was performed showing myeloproliferation with megakaryocytic hyperplasia. Cytogenetic analysis revealed a 46,XY,t(14;22)(q23;q13) karyotype. The patient had no splenomegaly and a LAP score was normal. A diagnosis of essential thrombocytosis was made. Hydroxyurea treatment was initiated for control of thrombocytosis. His nail discoloration improved. He continued with a normal CBC and normal differential for 18 months. The patient had no symptomatic complaints when a routine CBC performed in the spring of 2003 showed a WBC of 32.8 \( \times 10^3 \) cells \( \mu L^{-1} \) (25% neutrophils, 4% lymphocytes, 25% monocytes, 15% basophils, 2% eosinophils, 30% blasts); hemoglobin 9.9 g dL\(^{-1} \); hematocrit 31.5%; platelets 218 \( \times 10^3 \) \( \mu L^{-1} \). A repeat bone marrow biopsy showed hypercellularity with myeloproliferation, basophilia and an increase in immature myeloblasts (~50% of nucleated cells). A clinical diagnosis of CML in myeloblastic crisis was made and cytogenetic studies were performed. Systemic chemotherapy was initiated. The patient obtained a hematologic remission and was subsequently treated with imatinib. He relapsed with blastic disease 5 months later and succumbed to complications of his disease.

Materials and methods

Cytogenetic studies
Metaphase preparations were made by standard methods and analyzed on G-banded preparations. Twenty metaphases were analyzed and the karyotype was described by standard ISCN nomenclature. Spectral karyotype (SKY) analysis was performed on metaphase preparations using a human SkyPaint Probe kit obtained from Applied Spectral Imaging (Carlsbad, CA, USA) according to the manufacturer’s protocol. SKY images were acquired with a SD300 Spectra cube mounted on a Nikon Eclipse 800 microscope by using a SKY optical filter (Chroma Technology, Brattleboro, VT, USA) and analyzed using SKY View software.

FISH was performed using BCR/ABL dual color, dual fusion (D-FISH) probe combined with an Aqua-labeled ASS probe mapped proximal to ABL at 9q34 (both probes were obtained from VYSIS, Downers Grove, IL, USA). Hybridization was performed using standard methods. Hybridization signals were analyzed on a Nikon Eclipse 600 microscope attached to a CytoVision imaging system (Applied Imaging, Santa Clara, CA, USA).

Results

Cytogenetic studies
Cytogenetic analysis done elsewhere on bone marrow mononuclear cells at initial presentation in 2001 revealed an unequivocal 46, XY, t(14;22)(q23;q13) karyotype. Cytogenetic testing performed in
July 2003 upon presentation to the medical center revealed a 46,XY,t(14;22)(q23;q13)[8]/46,XY, idem,t(13;17)(q12;q22)[9]/47,XY,idem, + 8[3] karyotype (Figure 1(a)) and immunohistochemical studies were positive for CD33, CD13, CD117, CD64, CD11c, HLA-DR and MPO antigens. To examine whether this complex karyotype was the result of variant Ph+ chromosome, a spectral karyotype (SKY) analysis was performed (Figure 1(b)).

A combined G-banding and SKY karyotype of 47,XY, + 8,der(9)t(5;9)(?;q34),t(13;17)(q12;q22), del(14)(q23),ins(22;14)(q13.1;q24q32)[cp25] was derived and present in all metaphases, which provided no direct evidence for the existence of a BCR/ABL gene fusion. A deletion of 14q was recognised, as what was thought to be a translocation of 14;22 by G-banding was discovered to be ins(22;14) by SKY. Based on a high clinical index of suspicion for CML, FISH was also performed using a dual color, dual fusion BCR/ABL probe to look for the presence of a Ph+ chromosome. It was observed that 99.5% of the inter-phase cells studied showed a pattern of two orange signals (one with highly reduced signal), one green signal and one fusion signal, consistent with the presence of the BCR-ABL gene fusion product (Ph+ chromosome) and deletion of the reciprocal partner. Analysis of metaphase chromosomes showed that the BCR/ABL fusion signal was present on the ins(22;14) chromosome and a reduced spectrum orange signal.

Figure 1. (a) A G-banded karyotype showing 46,XY, + 8,t(13;17)(q12;q22),t(14;22)(q23;q13). Arrows indicate abnormal chromosomes. (b) A SKY karyotype showing 47,XY, + 8,der(9)t(5;9)(?;q34),t(13;17)(q12;q22),del(14)(q23),ins(22;14)(q13.1;q24q32). Abnormalities are indicated.
on der(9) chromosome. This pattern of signals was suggestive of the presence of BCR/ABL fusion of the t(9;22) and a deletion on the der(9)t(5;9) involving the 3' BCR sequence. To confirm the deletion on der(9), FISH was also performed using the 9q (ASS) probe combined with BCR/ABL probe (Figure 2).

The ASS probe was present as a residual signal on the der(9) chromosome, suggesting a large part of the gene is deleted. This result again confirms the presence of a deletion on der(9). All metaphase and interphase cells with BCR/ABL fusion showed the same pattern; The experiment was replicated and both times scored by two different investigators. Overall, these results are suggestive of deletion of the most part of ASS gene, 5' part of the ABL gene and the 3' BCR sequence. Based on these results, a diagnosis of CML, with a cryptic BCR-ABL fusion and der(9) deletion, presenting with a clinical thrombocytemic onset was made.

**RT-PCR for BCR-ABL**

To confirm the presence of a standard BCR/ABL translocation, RNA was extracted from the patient’s white cells using TriazolTM and 2 μg of patient RNA was reverse transcribed using Superscript M-MLV reverse transcriptase, followed by 2 rounds of PCR using previously published primers for the P210 transcript. The result was positive for the typical chimeric message.

**Discussion**

Essential thrombocythemia is a diagnosis of exclusion. It is a clonal myeloproliferative disorder which is limited to the megakaryocytic series. ET has clinical heterogeneity, with many patients having a relatively benign course over many years. It is rare to find chromosomal abnormalities in ET, estimated to be present in only 5–10% of cases by metaphase cytogenetics [14]. The Ph+ chromosome is the most commonly found abnormality and there is considerable evidence that Ph+ET may represent a ‘forme fruste’ of early chronic phase CML. CML is a chronic myeloproliferative disorder defined by the presence of the Ph+ chromosome, a chromosomal derivative formed by the reciprocal translocation of the long arms of chromosomes 9 and 22. This characteristic translocation takes place between the 5' end of the breakpoint cluster region (BCR) gene located at 22q11.2 and the 3' end of the c-ABL proto-oncogene (ABL1) located at 9q34, forming a BCR-ABL fusion gene that has a constitutively active Abl tyrosine kinase [15]. The Ph+ chromosome is seen during standard cytogenetic analysis in 85–95% of cases of CML, with the remaining 5–15% of cases showing variant Ph+ chromosomes or cryptic BCR-ABL rearrangements [16–21]. Case reports have described a translocation t(14;22), similar, but not identical to that seen in the patient, as both a simple and complex Philadelphia chromosome variant [22–24]. A number of studies have suggested that these variant translocations have prognostic importance [11,25]. As cytogenetic analysis can miss up to 10% of cases of CML, molecular tests for the BCR-ABL fusion product have been developed for use when a Ph+ chromosome cannot be identified. Southern blotting [26], RT-PCR and FISH [27,28] have all been used to identify the BCR-ABL gene rearrangement.

The patient was found to have a pattern of 2 orange signals, 1 green signal and 1 fusion signal by D-FISH. The solitary green signal and one of the solitary orange probes represent copies of the BCR and ABL genes on the normal chromosomes 9 and 22, respectively. The fusion probe is consistent with the presence of a BCR-ABL fusion gene on the derivative chromosome ins(22;14). The classic t(9;22) normally creates a reciprocal ABL-BCR fusion which is seen in the D-FISH assay as a second fusion signal on the derivative chromosome 22 [29,30]. In this patient, the second solitary orange probe seen on der(9) represents the 5' ABL portion of the reciprocal fusion, without the expected 3' BCR. The lack of a third green signal suggests that this region of genetic material has been deleted in...
the multiple recombination events which formed the cryptic BCR-ABL fusion and complex karyotype seen in the patient. The dual fusion FISH probes reduce the false positive rate to almost zero for identifying the reciprocal fusion product [31–33]. However, the use of the dual fusion probe led to the observation that a significant number of patients with clinically apparent CML lacked all or part of the reciprocal fusion product [11]. These studies have revealed that deletions on der(9) are a powerful and independent marker for poor prognosis in CML [9–11]. In the present case the prognostic implications of a derivative chromosome 9 deletion also appear to be negative.

Dual color, dual fusion FISH thus offers both diagnostic and prognostic information in patients with suspected CML. Since survival differences in patients with der(9) deletions appear to be partially abrogated when patients are treated with imatinib [13], the test provides useful treatment information as well. However, the limitation of FISH is that it does not identify the presence of an active bcr-abl tyrosine kinase in the cell. A possible mechanism by which the der(9) deletions may confer a more severe phenotype may be the loss of ABL-BCR transcript. Since the FISH probes range from 300–650 kb in size, small, but clinically important, deletions may not be detected with this system. The prognostic relevance of such deletions has not been rigorously studied and published reports indicate that loss of ABL-BCR transcript alone does not confer a poor prognosis [34,35]. It is of interest that SKY analysis was unable to identify this complex translocation.

The analysis was confounded by a complex chromosomal rearrangement that lacked the reciprocal fusion product normally found on derivative chromosome 9 which would also have suggested the presence of a derivative BCR/ABL rearrangement. Cytogenetic abnormalities in ET are rare and it is believed this is the first report of a patient with Ph+ ET, showing a deletion on der(9) with a variant Ph+ chromosome. The clinical behavior of the patient in this case report suggests that this syndrome behaves more like CML than ET, in particular with the poor prognosis of those CML patients with der(9) Ph+ variants, even with imatinib therapy. Since a functional BCR-ABL gene product is theoretically possible with the insertion of less than 350 kB of DNA, more specific identification of any clinically suspected BCR/ABL rearrangement in patients with ET must be investigated with molecular techniques such as dual color, dual fusion FISH. The findings in this patient argue for cytogenetic and FISH testing of all patients with suspected ET.

References

1. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematologica 2002;108:55–65.
2. Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genetics & Cytogenetics 1996;89:74–76.
3. Fadilah SA, Cheong SK. BCR-ABL positive essential thrombocythemia: a variant of chronic myelogenous leukemia or a distinct clinical entity: a special case report. Singapore Medical Journal 2000;41:595–598.
4. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Seminars in Hematology 1997;34:29–39.
5. Pajor L, Kereslai L, Zsidral K, Nagy Z, Vass JA, Jakso P, Radvary G. Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation. Histopathology 2003;42:53–60.
6. Aviram A, Blickstein D, Stark P, Luboshitz J, Bairey O, Prokocimer M, Shklai M. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leukemia & Lymphoma 1999;33:77–82.
7. Marasca R, Luppi M, Zucchin P, Longo G, Torelli G, Emilia G. Might essential thrombocythemia carry Ph anomaly? Blood 1998;91:3084–3085.
8. Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B, Ridell B, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Annals of Hematology 2004;83:504–512.
9. Hunsley BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. [comment]. Blood 2001;98:1732–1738.
10. Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, et al. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes, Chromosomes & Cancer 2003;37:291–299.
11. Reid AG, Hunsley BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology 2003;121:419–427.
12. Hunsley BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160–1168.
13. Hunsley BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205–2212.
14. Mitelman. NCI Mitelman Database of Chromosome Aberrations in Cancer 2004. Available online at: http://cgap.nci.nih.gov/Mitelman. Accessed 2 April 2003.
15. Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
16. Markovic VD, Bouman D, Bayani J, Al-Maghrabi J, Kamel-Reid S, Squire JA. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia;2000;14:1157–1160.

17. Bartram CR, Carbonell F. bcr rearrangement in Ph-negative CML. Cancer Genetics & Cytogenetics 1986;21:183–184.

18. Shtalrid M, Talpaz M, Blick M, Romero P, Kantarjian H, Taylor K, et al. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. Journal of Clinical Oncology 1988;6:1569–1575.

19. Storlazzi CT, Anelli L, Surace C, Loncoce A, Zagaria A, Nanni M, et al. Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia. Cancer Genetics & Cytogenetics 2002;136:141–145.

20. Becher R, Qiu JY, Parr A, Wendehorst E, Schmidt CG. Seven variants including four new Philadelphia translocations. Cancer Genetics & Cytogenetics 1990;44:181–186.

21. Dube I, Dixon J, Beckett T, Grossman A, Weinstein M, Benn P, et al. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. Genes in Chromosomes Cancer 1989;1:106–111.

22. Mantzourani M, Stamatopoulos K, Abazis D, Kontopidou F, Viniou N, Pangalis GA, et al. Molecular demonstration of BCR/ABL fusion in two cases with chronic myeloproliferative disorder carrying variant Philadelphia t(14;22)(q32;q11). Cancer Genetics & Cytogenetics 1996;91:82–87.

23. Ferro MT, San Roman C, Guzman M, Larana JG, Ordriozola J. Translocation t(14;22)(q32;q11): a special variant of the Philadelphia chromosome? Cancer Genetics & Cytogenetics 1986;20:167–170.

24. Browett PJ, Cooke HM, Secker-Walker LM, Norton JD. Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia. Cancer Genetics & Cytogenetics 1989;37:169–177.

25. Yehuda O, Abelowich D, Ben-Neriah S, Sverdlin I, Cohen R, Varadi G, et al. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genetics & Cytogenetics 1999;114:100–107.

26. Benn P, Sopher L, Eisenber A. Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer Genetics & Cytogenetics 1987;29:1–7.

27. Cox MC, Maffeï L, Buffolino S, Del Poeta G, Venditti A, Cantonetti M, et al. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias. American Journal of Clinical Pathology 1998;109:24–31.

28. Tbakhi A, Pettay MT, Sreenan JJ, Abdel-Razeq H, Kalaycio M, Hoeltge G, et al. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders. American Journal of Clinical Pathology 1998;109:15–23.

29. Reddy KS, Grove B. A Philadelphia-negative chronic myeloid leukemia with a BCR/ABL fusion gene on chromosome 9. Cancer Genetics & Cytogenetics 1998;107:48–50.

30. Primo D, Tabenerno MD, Rasillo A, Sayagues JM, Espinosa AB, Chillon MC, et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003;17:1124–1129.

31. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997;90:1395–1402.

32. Grand FH, Chase A, Iqbal S, Nguyen DX, Lewis JL, Marley SB, et al. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia. Genes, Chromosomes & Cancer 1998;23:109–115.

33. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998;91:3357–3365.

34. Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002;99:4547–4553.

35. de la Fuente J, Mere K, Steer EJ, Muller M, Szydlo RM, Maywald O, et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.[comment]. Blood 2001;98:2879–2880.